Several age predictors based on DNA methylation, dubbed epigenetic clocks, have been created in recent years, with the vast majority based on regularized linear regression. This study explores the improvement in the performance and interpretation of epigenetic clocks using deep learning. First, we gathered 142 publicly available data sets from several human tissues to develop AltumAge, a neural network framework that is a highly accurate and precise age predictor. Compared to ElasticNet, AltumAge performs better for within-data set and cross-data set age prediction, being particularly more generalizable in older ages and new tissue types. We then used deep learning interpretation methods to learn which methylation sites contributed to the final model predictions. We observe that while most important CpG sites are linearly related to age, some highly-interacting CpG sites can influence the relevance of such relationships. Using chromatin annotations, we show that the CpG sites with the highest contribution to the model predictions were related to gene regulatory regions in the genome, including proximity to CTCF binding sites. We also found age-related KEGG pathways for genes containing these CpG sites. Lastly, we performed downstream analyses of AltumAge to explore its applicability and compare its age acceleration with Horvath’s 2013 model. We show that our neural network approach predicts higher age acceleration for tumors, for cells that exhibit age-related changes in vitro, such as immune and mitochondrial dysfunction, and for samples from patients with multiple sclerosis, type 2 diabetes, and HIV, among other conditions. Altogether, our neural network approach provides significant improvement and flexibility compared to current epigenetic clocks for both performance and model interpretability.

Aging has become one of the fastest-growing research topics in biology. However, exactly how the aging process occurs remains unknown. Epigenetics plays a significant role, and several epigenetic interventions can modulate lifespan. This review will explore the interplay between epigenetics and aging, and how epigenetic reprogramming can be harnessed for age reversal. In vivo partial reprogramming holds great promise as a possible therapy, but several limitations remain. Rejuvenation by reprogramming is a young but rapidly expanding subfield in the biology of aging.

Several age predictors based on DNA methylation, dubbed epigenetic clocks, have been created in recent years. Their accuracy and potential for generalization vary widely based on the training data. Here, we gathered 143 publicly available data sets from several human tissues to develop AltumAge, a highly accurate and precise age predictor based on deep learning. Compared to Horvath's 2013 model, AltumAge performs better across both normal and malignant tissues and is more generalizable to new data sets. Interestingly, it can predict gestational week from placental tissue with low error. Lastly, we used deep learning interpretation methods to learn which methylation sites contributed to the final model predictions. We observed that while most important CpG sites are linearly related to age, some highly-interacting CpG sites can influence the relevance of such relationships. We studied the associated genes of these CpG sites and found literary evidence of their involvement in age-related gene regulation. Using chromatin annotations, we observed that the CpG sites with the highest contribution to the model predictions were related to heterochromatin and gene regulatory regions in the genome. We also found age-related KEGG pathways for genes containing these CpG sites. In general, neural networks are better predictors due to their ability to capture complex feature interactions compared to the typically used regularized linear regression. Altogether, our neural network approach provides significant improvement and flexibility to current epigenetic clocks without sacrificing model interpretability.